Lataa...
Olmesartan medoxomil: current status of its use in monotherapy
Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks’ treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2006
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1994016/ https://ncbi.nlm.nih.gov/pubmed/17323586 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|